Compare Charles River Laboratories Intl. Inc (CRL) vs iShares China Large-Cap ETF (FXI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs iShares China Large-Cap ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while iShares China Large-Cap ETF trades at $34.25 (market cap $3.86B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 3.7× iShares China Large-Cap ETF's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and iShares China Large-Cap ETF for 150 Days on average.
| CRL | FXI | |
|---|---|---|
Market Cap | $14.23B | $3.86B |
Volume | 1,176,885 | 16,323,837 |
Sector | Health | — |
52-Week High | $310.77 | $41.08 |
52-Week Low | $149.93 | $31.59 |
Typical Hold Time | 33 Days | 150 Days |
Enterprise Value | $17.06B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
FXI trades at $34.25, up 2.48% today but facing significant technical headwinds with a bearish overall signal. The ETF shows compelling valuation metrics with a P/E ratio of 11.10 versus the S&P 500's 22.54, offering potential value for investors seeking China exposure. Recent developments include the Trump-Xi summit in late September 2026, which may provide incremental risk reduction in U.S.-China relations.
The outlook remains cautious due to China's economic challenges including industrial overcapacity and weak domestic consumption. While the valuation discount presents opportunity, geopolitical risks and technical weakness suggest limited near-term upside. Key catalysts include China's monetary policy stance and progress on trade relations with the U.S.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →
